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ABSTRACT
In the treatment of atopic dermatitis ultraviolet therapy is considered the second line of treatment, when ad-
verse reactions occur and control is difficult with topical steroid treatment given as first-line treatment. Recently,
ultraviolet A-1 (UVA1, 340―400 nm) therapy and narrow-band UVB (311 nm) therapy have been developed and
applied to treatment of refractory skin diseases. In Europe, narrow-band UVB therapy is already used more
often than psoralens plus ultraviolet A (PUVA) therapy for atopic dermatitis, psoriasis and several other skin
diseases. Another newly developed device that has improved and expanded the spectrum of skin diseases
amenable to phototherapy is UVA1. With this modality, doses of UVA1 (340 to 400 nm) up to 130 Jcm2 are de-
livered to diseased skin. UVA1 was first used to treat patients with atopic dermatitis, but it has since been found
to be efficacious in several other skin diseases, such as localized scleroderma, where other therapeutic options
are limited. These two newly developed phototherapies demonstrate that the introduction of new spectra into
dermatologic phototherapy has broadened and improved phototherapy as it relates to established indications
such as atopic dermatitis.
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INTRODUCTION
Ultraviolet (UV) therapy is used for refractory skin
disease when topical steroid treatment is not effec-
tive. Psoralens plus ultraviolet A (PUVA) therapy has
been used effectively for general-purpose treatment
for 30 years throughout the world. This review pre-
sents an outline of newly developed photothera-
pies, i.e.,ultraviolet A-1 (UVA1, 340―400 nm) therapy
and narrow-band UVB (311 nm) therapy for atopic
dermatitis．
The first line of treatment for atopic dermatitis con-
sists of topical steroid and moisturizer treatment, ac-
companied with guidance of treatment on lifestyle
and removal of any causes of skin irritation. UV ther-
apy is used as the second line, when adverse reac-
tions occur and control is difficult with topical steroid
treatment given as first-line treatment. Actually, long-
term remission can be obtained by response to UV
therapy, and it may be possible to reduce the class of
steroid used. In addition, with UV therapy the dosage
of topical steroid can be reduced even if there had
been resistance to topical therapy alone . Recently ,
narrow-band UVB therapy and UVA1 therapy have
been developed and applied to treatment of refractory
skin diseases. These phototherapies employ selective
wavelengths to reduce carcinogenicity for safety and
to increase the effectiveness. Narrow-band UVB ther-
apy uses a very narrow wavelength band of 311―312
nm (Fig. 1A). For moderate and chronic cases, it can
be combined with topical steroid treatment . UVA1
phototherapy uses a wavelength of 340―400 nm (Fig.
1B). The exposure dose can be relatively high be-
cause the short wavelength, UVA2 (320―340 nm),
which causes erythema, is removed. This is not the
case with conventional UVA, which can therefore not
be used in large quantities, and has few indications
even though it has the same spectral distribution as
UVA1 in the fluorescent tube. For acute and severe
cases, it can be used as monotherapy. It is thought
that UVA1 therapy is equally or more effective than
PUVA therapy in a treatment of atopic dermatitis．
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Fig. 1 Spectra of narow-band UVB (A) and UVA1 (B)
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Fig. 2 Phototherapeutic approach for atopic dermatitis. 
UVA1 therapy may not be performed in atopic dermatitis 
with UVA-related photosensitivity.  It is necessary to exclu-
de the photosensitivity prior to initiation of UVA1 photo-
therapy.
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In general, symptomatic phototherapy of acute, se-
vere exacerbation of atopic dermatitis may be
achieved with UVA1, PUVA, and extracorporeal pho-
tochemotherapy , whereas conventional UVAUVB
and narrow-band UVB therapy represent photothera-
peutic modalities which are primarily indicated for
treatment of chronic stages of this disease (Fig. 2).
Narrow-band UVB phototherapy has proved to be an
ideal modality for maintenance therapy once high-
dose UVA1 has been used in the initial phase of man-
agement of an acute, severe exacerbation of atopic
dermatitis.1 If high-dose UVA1 therapy is not avail-
able , severe atopic dermatitis should be controlled
prior to the start of phototherapy by aggressive topi-
cal steroid therapy or systemic immunosuppressive
modalities such as oral steroid or cyclosporin A．
NARROW-BAND UVB THERAPY FOR
CHRONIC, MODERATE ATOPIC DERMATI-
TIS
Narrow-band UVB therapy, broadband UVB therapy,
combined UVAUVB therapy, broadband UVA ther-
apy, and low-dose UVA1 therapy are effective treat-
ments in mild and moderate atopic eczema, but are
not effective in patients with acute severe excacerba-
tion of their disease.1-6 These forms of UV photother-
apy are usually not employed as monotherapeutic ap-
proaches but rather are used in combination with
topical steroid treatment in order to reduce the need
for steroid application. All of these therapies are con-
sidered to be relatively safe , even if used over ex-
tended periods of time, and they should be used to in-
duce long-term improvement. Studies directly com-
paring all the different forms of UV therapy for
chronic , moderate atopic dermatitis have not been
performed, but recent trials indicate that either UVA
UVB 4,5 combination therapy or narrow-band UVB
therapy6 is superior to conventional broadband UVB,
broadband UVA, or low-dose UVA1 therapy. Also,
narrow-band UVB therapy appears to be equivalent to
bath-PUVA therapy for this indication.7 The most fre-
quent complaint of patients undergoing phototherapy
for atopic dermatitis relates to worsening of itch and
induction of sweating by heat, which may be associ-
ated with UV, in particular UVA, therapy. In a recent
study, George et al. incorporated air-conditioning into
a narrow-band UVB irradiation unit.3 By employing
50 100 W-W TL01 lamps equipped with reflectors, a
UVB output of 5 mWcm2 was achieved, which re-
sulted in maximum treatment times of less than 10
minutes. In this well-designed study, use the amount
of steroids used by patients with moderate, chronic
atopic dermatitis was monitored 12 weeks prior to
phototherapy, during 12 weeks of phototherapy, and
followed up for 24 weeks after cessation of photother-
apy. Start of narrow-band UVB therapy not only de-
creased the total clinical score, but also substantially
reduced the use of potent steroids. These beneficial
effects were still present in the majority of patients 6
months after cessation of phototherapy. These stud-
ies indicate that narrow-band UVB therapy may rep-
resent the phototherapeutic modality of choice to in-
duce long-term improvement in patients with atopic
dermatitis. They have recently been confirmed by an
independent report, which suggested that no special
cooling system is required in order to achieve the ex-
cellent therapeutic effects．
UVA1 PHOTOTHERAPY FOR ACUTE , SE-
VERE ATOPIC DERMATITIS
The rationale for employing UVA1 radiation, that is,
long wavelength UVA radiation (340―400 nm), in the
treatment of patients with atopic dermatitis was based
on immunological studies in which it was demon-
strated that exposure of human skin to a single dose
of 130 Jcm2 UVA1 radiation was associated with ab-
rogation of epidermal Langerhans cell function to ac-
tivate alloreactive T cells.8 At the same time, evidence
was accumulating that epidermal Langerhans cells ,
by virtue of their capacity to bind IgE molecules, may
play an important role in inhalant allergen-mediated T
cell activation and thus be of critical importance for
the pathogenesis of atopic dermatitis . 9 In addition ,
176 Allergology International Vol 54, No2, 2005 www.js-allergol.gr.jp
Morita A
clinical studies comparing the efficacy of broadband
UVB therapy versus UVAUVB therapy in the man-
agement of patients with atopic dermatitis indicated
that the therapeutic effectiveness of conventional
UVB therapy may be significantly improved by in-
creasing the UVA portion of the action spectrum
(UVAUVB therapy).2 The therapeutic effectiveness
of UVA1 irradiation in the management of patients
with atopic dermatitis was first assessed in a pilot
study, in which patients with acute, severe exacerba-
tion of atopic dermatitis were exposed one time per
day to a single dose of 130 Jcm2 UVA1 (high-dose
UVA1 therapy) for 15 consecutive days.10 The thera-
peutic effectiveness of UVA1 therapy was compared
with that of a conventional UVAUVB therapy by em-
ploying both modalities as a monotherapy, that is, ad-
ditional treatment was restricted in both groups to
the use of emollients. Assessment of clinical scores
demonstrated that UVA1 therapy was efficient in
promptly inducing an improvement in clinical symp-
toms of patients with atopic dermatitis , and that in
comparison to conventional UVAUVB therapy, sig-
nificant differences in favor of UVA1 therapy were ob-
served after 6 and 15 exposures. Similarly, elevated
serum levels of eosinophil cationic protein in patients
with atopic dermatitis were significantly decreased by
UVA1 therapy, but remained essentially unaltered in
patients undergoing UVAUVB therapy. These pre-
liminary but promising results indicated that UVA1
therapy may represent a novel phototherapeutic mo-
dality, which could be employed as a monotherapeu-
tic approach to treat patients with acute, severe exac-
erbation of atopic dermatitis . During subsequent
years, these original observations were confirmed by
numerous reports , which mainly represent uncon-
trolled, open, and sometimes not even comparative
studies.11-15 In a subsequent multicenter trial, a total
of 53 patients were therefore randomly assigned to
either UVA1 therapy (once daily 130 Jcm2, total of
10 days) or conventional UVAUVB therapy (once
daily, MED-dependent , total of 10 days) or topical
treatment with fluocortolone ( once daily for 10
days).16 This study is the only one to provide a multi-
centric evaluation of the efficacy of UVA1 therapy in a
controlled randomized fashion. It was observed that
after 10 treatments, patients in all three groups had
improved, but the decrease in total clinical scores and
thus clinical improvement was significantly greater in
patients receiving topical steroid or UVA1 therapy, as
compared with UVAUVB therapy. Under these con-
ditions, UVA1 therapy, as compared with topical ster-
oid treatment, was significantly better at day 10 of
therapy in reducing the total clinical score . These
clinical observations were corroborated by laboratory
assessments, in which serum levels of eosinophil cat-
ionic protein as well as peripheral blood eosinophilia
were compared before and after therapy between the
three treatment groups. All together, the multicenter
trial results indicate that UVA1 therapy and topical
steroid treatment are superior to conventional UVA
UVB therapy in the management of patients with
acute, severe exacerbation of atopic dermatitis. UVA1
therapy may not be performed in atopic dermatitis pa-
tients with UVA1-sensitive atopic dermatitis or photo-
dermatoses such as polymorphic light eruption.17 It is
necessary to exclude these diseases prior to initiation
of UVA1 therapy. This can easily be accomplished by
photoprovocation testing. Except for eczema herpeti-
catum, no acute side effects have been observed in
any of the atopic dermatitis patients treated with
UVA1. No other side effects have been observed, al-
though potential carcinogenic risk is a theoretical
concern.17 Exposure of hairless, albino Skh-hrl mice
to UVA 1 radiation has been shown to induce
squamous cell carcinoma. The actual contribution of
UVA 1 radiation to the development of malignant
melanoma in humans is currently under debate and
at this point cannot be excluded. Until more is known
about UVA1 therapy, its use should be limited to peri-
ods of severe, acute exacerbation, and, in general ,
one treatment cycle should not exceed 10―15 continu-
ously applied exposures and should not be repeated
more than once a year. For the same reasons UVA1
therapy should not be recommended for patients
younger than 18 years of age.17 In order to assess po-
tential long-term side effects of UVA1 phototherapy in
a systematic manner, a prospective longitudinal study
has been started in Europe to monitor patients
treated with UVA1 phototherapy for the development
of skin cancer and photoaging．
The therapeutic effectiveness of UVA1 therapy is
dose-dependent. Low-dose UVA1 (30 Jcm2 ) is less
effective than UVAUVB therapy , 5 whereas high-
dose UVA1 therapy (130 Jcm2 ) is superior to UVA
UVB phototherapy.16 In addition , a medium-UVA1
dosage schedule (50 Jcm2 ) was superior to a low-
dose UVA1 regimen (10 Jcm2), whereas no signifi-
cant difference was detected in a bilateral comparison
study between a medium- and a high-dose regi-
men.13,18
ACTION MECHANISMS UNDERLYING UVA1
PHOTOTHERAPY FOR ATOPIC DERMATI-
TIS
Substantial progress has been made in understanding
the photoimmunological mechanisms responsible for
the therapeutic effectiveness of UVA 1 therapy in
atopic dermatitis.19 From these studies it appears that
UVA1 therapy is capable of downregulating in situ ex-
pression of IFN-γ in lesional skin of patients with
atopic dermatitis. This inhibitory effect was relatively
specific since in the same biopsies expression of nei-
ther the housekeeping gene β-actin nor the cytokine
IL-4 was reduced. Inhibition of IFN-γ expression in
atopic eczema may not only be achieved by UVA1
therapy, but could also be seen after topical steroid
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Fig. 3 UVA1 iradiation induces apoptosis in a dose- and 
time-dependent manner.  Atopen-specifc T cels were iradi-
ated with the indicated doses (10―30 J/cm2). After 24 hours, 
the rate of apoptosis was analysed by flow cytometry.  At 
the dose of 30 J/cm2, the rate of apoptosis was analysed at 
the indicated time points (4―24 hours).
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application and most likely represents a general
mechanism by which various treatment forms induce
symptomatic relief in atopic dermatitis.20 Downregu-
lation of IFN-γ expression in atopic eczema is the con-
sequence of direct effects of UVA1 radiation on Th1
cells present within the dermal infiltrate．
Phototherapy of atopic dermatitis employing UVA1
(340―400 nm ), which effectively penetrates the der-
mal layers of human skin and thus has the potential
to directly affect intradermal T cells , 21 has been
shown to be superior to short wavelength UVB radia-
tion,22 which is almost exclusively absorbed by the
epidermis.21 Accordingly, successful UVA1 therapy of
atopic dermatitis was associated with significant
downregulation of the in situ expression of T-helper
cell derived cytokines as well as significant reduction
in the number of intradermal CD4+ T cells.20 These
observations led us to speculate that UVA 1 pho-
totherapy may act through depletion of skin-
infiltrating T-helper cells. Our previous study demon-
strated that UVA1 phototherapy induced apoptosis in
T-helper cells present in eczematous skin of atopic
dermatitis patients . 23 We also show that in vitro
UVA1 irradiation-induced apoptosis in atopen-specific
human T-helper cells from atopic dermatitis was me-
diated by the FASFAS-ligand system and induced
through the generation of singlet oxygen.23 In order
to assess whether UVA1 phototherapy of atopic der-
matitis patients was accompanied by the induction of
apoptosis in skin-infiltrating T-helper cells, sequential
biopsies were taken from eczematous skin of five pa-
tients before the 1st, and after the 1st, 2nd, 3rd, 4th
and 10th exposure to UVA1 radiation. In all patients,
UVA1 phototherapy led to a significant improvement
of skin symptoms, as was assessed by a clinical scor-
ing system (total score before UVA1 phototherapy :
65.4 ± 6.2 ; total score after UVA1 phototherapy :
18.2 ± 3.4 ; p< 0.001).24 Skin specimens were analyzed
for apoptotic cells using the TUNEL assay, followed
by an anti-CD4 staining to detect T-helper cells. Be-
fore therapy, numerous CD4+ cells were present in-
tradermally in eczematous skin. Already after the 1st
UVA1 radiation exposure, CD4+, apoptotic cells were
detected. During subsequent UVA1 treatments, the
number of double positive cells was further in-
creased, whereas the total number of CD4+ cells de-
creased. After ten exposures, the total number of in-
tradermally located, CD4+ T-cells had been signifi-
cantly diminished, and remaining cells almost exclu-
sively showed signs of apoptosis. In order to assess
whether UVA1 radiation is capable of directly induc-
ing apoptosis in skin-infiltrating T-helper cells ,
atopen-specific T-cells, which had been derived from
eczematous skin of atopic dermatitis patients,25 were
employed. In atopen-specific human T-helper cells, in
vitro UVA1 irradiation induced apoptosis in a dose-
and time-dependent manner (Fig . 3). Significant
apoptosis was already detectable 4 hours after expo-
sure, reaching a maximum 24 hours after irradiation
with 30 Jcm2 UVA1 radiation. In order to determine
the involvement of the FASFASL system in UVA1
radiation-induced human T-helper cell apoptosis, FAS
and FASL expression was measured in irradiated
cells using FACS analysis. Before UVA1 radiation ex-
posure, FASL molecules were not present on the cell
surface, but significant FASL surface expression was
detected in UVA1-irradiated cells already 4 hours af-
ter exposure．
Induction of T-cell apoptosis was observed regard-
less of whether broad-band UVB or narrow-band
UVB phototherapy was employed. It should be noted,
however , that because of its physical properties , a
much greater level of narrow-band UVB radiation
penetrates into human dermis, and therefore apopto-
sis occurs in both epidermal and dermal T cells. This
difference may at least partially explain the clinical
observation that narrow-band UVB phototherapy is
superior to broad-band UVB phototherapy for the
treatment of psoriasis.26,27
However , the mechanisms by which UVA1 and
UVB radiation induce T-cell apoptosis differ mark-
edly. In general, UVA1 radiation can cause prepro-
grammed cell death (early apoptosis), which is pro-
tein synthesis independent, as well as programmed
cell death (late apoptosis), which requires de novo
protein synthesis.28 In contrast, UVB irradiation (and
also PUVA treatment) exclusively induces late apop-
tosis.29 UVA1 radiation is able to cause both early and
late apoptosis and UVA1-R-induced singlet oxygen
generation is the initiating event leading to T-cell
apoptosis.23 Singlet oxygen production induced the
expression of Fas ligand molecules on the surface of
UVA1-irradiated T cells. Subsequent binding of Fas
ligand to Fas on the same or neighboring T cells was
then shown to be responsible for T cell apoptosis .
The key role of singlet oxygen in eliciting early apop-
tosis in human T cells has recently been corrobo-
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rated in an independent study employing Jurkat cells.
UVA1 radiationsinglet oxygen has been postulated
to act on mitochondria and induce Jurkat cell apopto-
sis by opening the megachannel and by decreasing
the mitochondrial membrane potential.29 The capac-
ity to induce early apoptosis in mammalian cells
seems to be highly specific for UVA1 radiation and
singlet oxygen, respectively. From a phototherapeu-
tic point of view, this qualitative difference suggests
that UVA1 phototherapy is superior to UVB or PUVA
therapy for skin diseases in which induction of apop-
tosis in pathogenetically relevant cells is of critical im-
portance. The unique properties of UVA1 radiation
have also stimulated interest in its therapeutic use for
patients with cutaneous T cell lymphoma.30 In vitro
studies indicate that malignant T cells are exquisitely
sensitive to UVA1 radiation-induced apoptosis.31
In addition to directly affecting epidermal and der-
mal T cells, UVA1 radiation may alter Th1 cell IFN-γ
expression via indirect mechanisms, e.g. by inducing
the production of anti-inflammatory cytokines such as
IL-10 by epidermal keratinocytes, which in turn may
act on T cells in a paracrine manner. In keeping with
this concept are in vitro studies demonstrating in-
creased expression of IL-10 mRNA and secretion of
IL-10 protein by cultured human keratinocytes follow-
ing UVA1 radiation exposure.32 Immunohistochemi-
cal studies employing biopsies obtained from patients
with atopic dermatitis undergoing UVA1 therapy indi-
cate that in addition to T cells and keratinocytes, epi-
dermal Langerhans cells as well as dermal mast cells
represent target cells for UVA1 radiation . 20 UVA1
therapy, in contrast to UVAUVB therapy, reduced
not only the relative number of IgE-bearing Langer-
hans cells in the epidermis, but also the number of
dermal CD1a+ Langerhans cells and mast cells. The
latter observation prompted the use of UVA1 therapy
in the treatment of patients with urticaria pigmentosa,
in which immediate and long-lasting remissions from
cutaneous and systemic symptoms could be
achieved.33
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